# TRUST-III (NCT06564324)

> A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT06564324
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Nuvation Bio Inc.
- Conditions: Non Small Cell Lung Cancer
- Interventions: Taletrectinib; Crizotinib
- Enrollment: 194
- Primary outcome: PFS (Assessed by BIRC)

## Indexed commentary on TRUST-III so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 9

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=trust-iii-nct06564324

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT06564324", "email": "<work email>"}; the inbox owner confirms by the emailed link.